美國雙特異性抗體市場規模、佔有率和趨勢分析報告：按類型和細分市場預測（2025-2033 年）

美國雙特異性抗體市場摘要

2024年美國雙特異性抗體市場規模估計為117.8億美元，預計2033年將達到2,719.5億美元。

預計從 2025 年到 2033 年，雙特異性抗體產業將以 40.1% 的複合年成長率成長。在美國，雙特異性抗體產業正經歷顯著成長，這主要得益於癌症和自體免疫疾病的增加以及對更精準標靶治療的強勁需求。

根據《自然綜述：臨床腫瘤學》（2024）報告，目前有超過200種雙特異性抗體處於臨床前或臨床開發階段。這些抗體大多被設計為免疫細胞銜接器，可針對兩種抗原，其雙標靶機制展現了其在精準腫瘤治療中的應用潛力。

此外，美國食品藥物管理局(FDA) 對多種雙特異性抗體的核准不斷增加，也促進了研發投入的增加。例如，2025 年 5 月，輝瑞與 3SBio 公司簽署了一項利潤豐厚的 SSGJ 707 授權協議，其中包括 12.5 億美元的首付和高達 48 億美元的里程碑付款。同樣，2025 年 6 月，百時美施貴寶公司與 BioNTech 公司達成合作，共同開發和商業化 BioNTech 公司在研的用於治療多種固態腫瘤的雙特異性抗體 BNT327，該協議價值高達 111 億美元。該協議包括 15 億美元的首付款、20 億美元的保證付款，以及根據研發、監管和商業里程碑支付的最高 76 億美元的額外款項。

在美國，由於全國癌症病例數量不斷增加，雙特異性抗體療法正變得越來越受歡迎。美國血液學會於2024年發表的一項研究調查了564名復發或難治性多發性骨髓瘤患者。其中，202名患者接受了雙特異性抗體治療，包括teclistamab（91%）、talquetamab（14%）和erlanatamab（3%）。這些療法的應用率從2022年的1例激增至2023年合格患者的45%，並在2024年中期達到54%。這種快速普及與FDA分別於2022年10月和2023年8月核准teclistamab和erlanatamab上市的時間相吻合。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章美國雙特異性抗體市場變數、趨勢與範圍

• 市場體系展望
  • 母市場展望
  • 相關市場展望
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
  • 產業挑戰
  • 產業機遇
• 產業分析工具
  • 波特五力分析
• 打入市場策略

第4章美國雙特異性抗體市場：按類型分類的估計和趨勢分析

• 美國雙特異性抗體市場按類型分類：主要結論
• 2024 年和 2033 年按類型分類的變異分析和市場佔有率
• 按類型分類，2021-2033 年
  • 發炎性疾病與自體免疫疾病
  • 癌症
  • 其他

第5章美國雙特異性抗體市場競爭格局

• 主要市場參與企業的最新趨勢和影響分析
• 公司分類
• 財務業績
• 產品基準測試
• 公司熱力圖/定位分析
• 策略規劃
• 公司簡介
  • Amgen
  • Roche
  • Genentech
  • Janssen
  • Immunocore

U.S. Bispecific Antibodies Market Summary

The U.S. bispecific antibodies market size was estimated at USD 11.78 billion in 2024 and is projected to reach USD 271.95 billion by 2033, growing at a CAGR of 40.1% from 2025 to 2033. The U.S. bispecific antibodies industry is undergoing remarkable growth, driven by the rising burden of cancer and autoimmune diseases and a strong demand for therapies with more precise targeting.

A Nature Reviews Clinical Oncology article (2024) states that over 200 bispecific antibodies are in preclinical or clinical development. Most of these antibodies are designed as immune-cell engagers targeting two antigens, highlighting their potential for precision oncology through dual-target mechanisms.

Furthermore, the rising approval by the U.S. Food and Drug Administration for various bispecific antibodies contributes to the growth of investment in research and development activities. For instance, in May 2025, Pfizer entered a high-value licensing agreement with 3SBio for SSGJ 707, including a USD1.25 billion upfront payment and up to USD 4.8 billion in milestone-based payouts. Similarly, in June 2025, Bristol Myers Squibb partnered with BioNTech in a deal worth up to USD 11.1 billion for the co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 for various solid tumor types, comprising USD 1.5 billion upfront, USD 2 billion in guaranteed payments, and as much as USD 7.6 billion in additional development, regulatory, and commercial milestones.

In the U.S., bispecific antibodies are becoming increasingly popular due to the rising number of cancer cases nationwide. A 2024 study published by the American Society of Hematology reported on 564 patients with relapsed or refractory multiple myeloma. Out of these patients, 202 were treated with bispecific antibodies, including teclistamab (91%), talquetamab (14%), and elranatamab (3%). The adoption of these treatments grew dramatically, from just one patient treated in 2022 to 45% of eligible patients in 2023 and reached 54% by mid-2024. This swift adoption corresponds with the FDA approvals of teclistamab in October 2022 and elranatamab in August 2023.

U.S. Bispecific Antibodies Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. bispecific antibodies market report based on type:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Inflammatory & Autoimmune Disorders
• Cancer
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources & Third-Party Perspectives
  • 1.3.4. Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Data Visualization
• 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Bispecific Antibodies Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Industry Challenges
  • 3.2.4. Industry Opportunities
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
• 3.4. Market Entry Strategies

Chapter 4. U.S. Bispecific Antibodies Market: Type Estimates & Trend Analysis

• 4.1. U.S. Bispecific Antibodies Market Type: Key Takeaways
• 4.2. Type Movement Analysis & Market Share, 2024 & 2033
• 4.3. U.S. Bispecific Antibodies Market Estimates & Forecast, By Type, 2021 To 2033 (USD Million)
  • 4.3.1. Inflammatory & Autoimmune Disorders
    • 4.3.1.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
  • 4.3.2. Cancer
    • 4.3.2.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
  • 4.3.3. Others
    • 4.3.3.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)

Chapter 5. U.S. Bispecific Antibodies Market - Competitive Landscape

• 5.1. Recent Developments & Impact Analysis by Key Market Participants
• 5.2. Company Categorization
• 5.3. Financial Performance
• 5.4. Product Benchmarking
• 5.5. Company Heat Map/ Positioning Analysis
• 5.6. Strategy Mapping
• 5.7. Company Profiles
  • 5.7.1. Amgen
    • 5.7.1.1. Company Overview
    • 5.7.1.2. Financial Performance
    • 5.7.1.3. Product Benchmarking
    • 5.7.1.4. Strategic Initiatives
  • 5.7.2. Roche
    • 5.7.2.1. Company Overview
    • 5.7.2.2. Financial Performance
    • 5.7.2.3. Product Benchmarking
    • 5.7.2.4. Strategic Initiatives
  • 5.7.3. Genentech
    • 5.7.3.1. Company Overview
    • 5.7.3.2. Financial Performance
    • 5.7.3.3. Product Benchmarking
    • 5.7.3.4. Strategic Initiatives
  • 5.7.4. Janssen
    • 5.7.4.1. Company Overview
    • 5.7.4.2. Financial Performance
    • 5.7.4.3. Product Benchmarking
    • 5.7.4.4. Strategic Initiatives
  • 5.7.5. Immunocore
    • 5.7.5.1. Company Overview
    • 5.7.5.2. Financial Performance
    • 5.7.5.3. Product Benchmarking
    • 5.7.5.4. Strategic Initiatives

List of Tables

• Table 1 U.S. Bispecific Antibodies Market Estimates and Forecast, By Type, 2021 - 2033 (USD Million)

List of Figures

• Fig 1 US Bispecific Antibodies Market Segmentation
• Fig 2 Information Procurement
• Fig 3 Primary Research Pattern
• Fig 4 Primary Research Approaches
• Fig 5 Primary Research Process
• Fig 6 Market Snapshot
• Fig 7 Type Segment Snapshot
• Fig 8 Competitive Landscape Snapshot
• Fig 9 US Bispecific Antibodies Market Value, 2024 (USD Million)
• Fig 10 US Bispecific Antibodies Market - Industry Value Chain Analysis
• Fig 11 US Bispecific Antibodies Market Dynamics
• Fig 12 US Bispecific Antibodies Market: Porter's Analysis
• Fig 13 US Bispecific Antibodies Market, By Type: Key Takeaways
• Fig 14 US Bispecific Antibodies Market, By Type: Market Share, 2024 & 2033
• Fig 15 Inflammatory & Autoimmune Disorders Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig 16 Cancer Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig 17 Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig 18 Key Company Categorization
• Fig 19 Strategic Framework